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Abstract: Mycobacterium tuberculosis (Mtb) has recently surpassed HIV/AIDS as the leading cause of
death by a single infectious agent. The standard therapeutic regimen against tuberculosis (TB) remains
a long, expensive process involving a multidrug regimen, and the prominence of multidrug-resistant
(MDR), extensively drug-resistant (XDR), and totally drug-resistant (TDR) strains continues to impede
treatment success. An underexplored class of natural products—the capuramycin-type nucleoside
antibiotics—have been shown to have potent anti-TB activity by inhibiting bacterial translocase I,
a ubiquitous and essential enzyme that functions in peptidoglycan biosynthesis. The present review
discusses current literature concerning the biosynthesis and chemical synthesis of capuramycin
and analogs, seeking to highlight the potential of the capuramycin scaffold as a favorable anti-TB
therapeutic that warrants further development.
Keywords: natural product; nucleoside; antibiotic; MraY; bacterial translocase I; Mycobacterium tuberculosis
1. Introduction
Tuberculosis (TB), primarily caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb), is
one of the oldest and deadliest infectious diseases known to humans. The World Health Organization
(WHO) has recently reported that TB affected approximately 10 million people and killed roughly
1.3 million people in 2017 alone [1–4]. Although global TB-related mortality rates have steadily
declined since the turn of the millennium, multidrug-resistant (MDR), extensively drug-resistant
(XDR), and totally drug-resistant (TDR) strains pose significant threats to this progress [1,3,5–9].
Consequently, there is an urgent need for discovering new therapeutics to treat TB, which will in part
help to offset the diminishing utility of the antibiotics currently used to treat TB. Capuramycin-type
nucleoside antibiotics, which represent one such possible new class, are natural products that were
re-discovered in the early 2000s and have significant promise for drug development as anti-TB
therapeutics. This review summarizes the discovery of the capuramycin-type nucleoside antibiotics;
progress toward defining their biosynthetic pathway; and synthetic, semisynthetic, and biocatalytic
studies aimed at generating analogs with potentially improved therapeutic value. For an in depth
description of Mtb and tuberculosis, including the major challenges in drug discovery and development,
we refer the reader to several excellent reviews [10–14] and publications cited herein.
2. Discovery, Mechanism of Action, and Structure of Capuramycin-Type Nucleoside Antibiotics
Bacterial translocase I (annotated as MraY in Escherichia coli, MurX in Mtb, and herein simply
abbreviated as TL1) is an unusual transmembrane enzyme that catalyzes the first committed membrane
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step of peptidoglycan biosynthesis [15–19]. TL1 transfers phospho-N-acetylmuramoyl-pentapeptide
(phospho-MurNAc-pentapeptide) onto the lipid carrier, undecaprenyl phosphate (C55-P), to produce
uridine-5′-phosphate (UMP) and lipid I (Figure 1) [20]. This catalytic activity has been shown to be
essential for the survival of Gram-positive, Gram-negative, and mycobacteria including Mtb [21–23].
In the early 2000s, Sankyo Co. (now Daiichi-Sankyo) recognized the potential of TL1 as an antibiotic
target and developed a high-throughput screen aimed at identifying compounds, particularly those
from bacterial extracts, that specifically inhibit TL1 activity in vitro [24–30]. A series of related
nucleoside natural products were isolated from this screen and confirmed to potently inhibit TL1 with
10 to 38 nM IC50 values [25,28,30]. Additional studies revealed a select set of the nucleoside-containing
natural products also have antibacterial activity as expected, including activity against Gram-positive
bacteria, such as Streptococcus pneumonia [25,28], and most species of mycobacteria, including Mtb [31].
Importantly, a representative TL1 inhibitor with anti-TB activity in vitro was shown to be effective in a
murine model of TB infection with no detectable toxicity [31].
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the genus of bacteria. 
Three related groups of nucleoside-containing natural products were discovered by Sankyo Co. 
and named A-500359s (Figure 2A, 1 to 5, 8 to 10), produced by Streptomyces griseus SANK 60196; A-
503083s (6, 7, 11, and 12), produced by Streptomyces sp. SANK 62799; and A-102395 (13), produced by 
Amycolatopsis sp. SANK 60206. Structural elucidation of A-500359s revealed three distinct chemical 
components: A uridine-5'-carboxamide (CarU), an unsaturated α-D-manno-pyranuronate, and L-
aminocaprolactam (L-ACL). A-500359 B (1) was shown to be identical to a known natural product 
named capuramycin, which was discovered in 1986 from Streptomyces griseus 446-S3 as part of a 
search for antibacterial agents [32,33]. Hence, we have termed the three groups as capuramycin-type 
antibiotics. The A-503083s differ from the A-500359s by the presence of a 2’-O-carbamoyl group, 
which has a minimal effect on TL1 inhibition and anti-TB activity. For both A-500359s and A503083s, 
deaminocaprolactam derivatives 8 to 12 were isolated from the producing strains, and these analogs 
were shown to have significantly reduced inhibitory activity against TL1 as well as reduced antibiotic 
activity. Nucleoside 13 differs from the other two groups by containing an arylamine-linked 
polyamide chain instead of the L-ACL. This substitution imparts 13 with the most potent TL1 
inhibition (IC50 = 10 nM) of the three groups but effectively eliminates all antibiotic activity including 
against Mtb. 
Figure 1. Depiction of the translocase I (TL1)-catalyzed reaction. TL1 transfers phospho-MurNAc-
pentapeptide to C55-P to produce UMP and Lipid I. The Mg2+-dependent translocase I-catalyzed
reaction occurs in the cytoplasm of the cell. The structure of TL1 from Aquifex aeolicus (Protein Data
Bank ID: 4J72; [18]). aL-Lys or L-diaminopimaleic acid (L-Dap) is found at this position depending on
the genus of bacteria.
Three related groups of nucleoside-containing natural products were discovered by Sankyo
Co. and named A-500359s (Figure 2A, 1 to 5, 8 to 10), produced by Streptomyces griseus SANK
60196; A-503083s (6, 7, 11, and 12), produced by Streptomyces sp. SANK 62799; and A-102395 (13),
produced by Amycolatopsis sp. SANK 60206. Structural elucidation of A-500359s revealed three distinct
chemical components: A uridine-5′-carboxamide (CarU), an unsaturated α-D-manno-pyranuronate,
and L-aminocaprolactam (L-ACL). A-500359 B (1) was shown to be identical to a known natural
product named capuramycin, which was discovered in 1986 from Streptomyces griseus 446-S3 as part of
a search for antibacterial agents [32,33]. Hence, we have termed the three groups as capuramycin-type
antibiotics. The A-503083s differ from the A-500359s by the presence of a 2′-O-carbamoyl group,
which has a minimal effect on TL1 inhibition and anti-TB activity. For both A-500359s and A503083s,
deaminocaprolactam derivatives 8 to 12 were isolated from the producing strains, and these analogs
were shown to have significantly reduced inhibitory activity against TL1 as well as reduced antibiotic
activity. Nucleoside 13 differs from the other two groups by containing an arylamine-linked polyamide
chain instead of the L-ACL. This substitution imparts 13 with the most potent TL1 inhibition
(IC50 = 10 nM) of the three groups but effectively eliminates all antibiotic activity including against Mtb.
The shared CarU and 4,5-dehydro-D-manno-pyranuronate of the capuramycin-type nucleoside
antibiotics are structural components not found in other natural products [34,35]. The former
is categorized as a high-carbon sugar nucleoside since the furanoside contains six contiguous
Molecules 2019, 24, 433 3 of 17
carbons in place of the D-ribose of the canonical uridine nucleoside. Several other, structurally
distinct high-carbon sugar nucleosides are known, including another category of TL1 inhibitors
highlighted by a high-carbon sugar nucleoside of seven contiguous carbons, 5′-C-glycyluridine (GlyU).
The GlyU-containing TL1 inhibitors, represented by the liposidomycin-type nucleoside antibiotics that
includes A-90289s and caprazamycins (Figure 2B), also have anti-TB activity in addition to efficacy
against other bacteria [36,37]. Another example of a group of natural products containing a high-carbon
sugar nucleoside is the polyoxins (Figure 2C), which contain six contiguous carbons in place of the
D-ribose of the canonical uridine [38]. In contrast to CarU, however, C-6’ of the polyoxin nucleoside is
a carboxylate that is part of a terminal α-amino acid. Unlike CarU- and GlyU-containing nucleoside
antibiotics, polyoxins do not inhibit TL1 but instead have antifungal activity due to selective inhibition
of chitin synthase [39].
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Figure 2. Structures of high-carbon sugar nucleosides. (A) Structure of the three major groups (A-
500359s, A-503083s, and A-102395) of capuramycin-type nucleoside antibiotics isolated from different 
bacterial strains. (B) Structure of representative 5’-C-glycyluridine (GlyU)-containing nucleoside 
antibiotics. (C) Structure of the antifungal compound polyoxin A. 
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The biosynthesis of capuramycin-type antibiotics was first interrogated using feeding 
experiments with isotopically labeled precursors in 2003 with the goal of elucidating the metabolic 
origin of each structural component [27]. A convergent biosynthetic approach was predicted from 
CarU, α-D-manno-pyranuronate, and L-ACL components, which were likewise proposed to be 
derived from uridine, D-mannose, and L-Lys, respectively. Using A-500359s as the model 
capuramycins, a 17-fold enrichment at the C-1′ position using [1-13C]D-ribose, 11-fold enrichment of 
the C-1′′ position using [1-13C]D-mannose, and a 16-fold enrichment of the C-1′′′ position using [1-
13C]L-Lys were found (Figure 3). The precursor of the C-5′ carboxamide of CarU, a unique feature of 
this family of nucleoside antibiotics as previously noted, was not readily apparent based on 
biochemical precedence. However, it was initially observed that A-500359s and polyoxins have high-
carbon sugar nucleosides with a C-6′ carbonyl functional group [27,38]. Since the origin of the C-5′ 
carboxylate of polyoxin was previously assigned to phosphoenolpyruvate on the basis of isotopic 
enrichment studies using [3-13C]pyruvate [40], the C-5' carboxamide of A-500359s was proposed to 
Figure 2. Structures of high-carbon sugar nucleosides. (A) Structure of the three major groups
(A-500359s, A-503083s, and A-102395) of capuramycin-type nucleoside antibiotics isolated from
different bacterial strains. (B) Structure of representative 5′-C-glycyluridine (GlyU)-containing
nucleoside antibiotics. (C) Structure of the antifungal compound polyoxin A.
3. i s t sis
3.1. I vestigation of recursors
The biosynthesis of capur mycin-type antibiotics was first interrogated usin fe ing experiments
with isotopically labeled precursors in 2003 with the goal of elucid ting the metabolic origin of
each structural component [27]. A convergent biosy thetic approach was predicted from CarU,
α-D-manno-pyranuron te, a d L-ACL components, which were likewise proposed t be erived
from uridine, D-man ose, and L-Lys, respectively. Using A-500359s as the model capuramycins,
a 17-fold enrichment at the C-1′ position using [1-13C]D-ribose, 11-fold enrichment of t e C-1′ ′
position using [1-13C]D-mannose, and a 16-fol enrichment of the C-1′ ′ ′ position using [1-13C]L-Lys
were found (Figure 3). The precursor of the C-5′ carboxamide of CarU, a unique featur of this
family of nucleoside antibiotics as previously noted, was not readily apparent based on biochemical
precedence. How v r, it was initially observed that A-500359s nd polyoxins have high-carbon su ar
nucleosides with a C-6′ carbonyl functional gro p [27,38]. Since the origin of C-5′ carboxylate
of polyoxin was previously assigned to phosphoenol yruvat on the basis f isotopic enrichment
studies using [3-13C]pyruvate [40], the C-5′ carboxamide of A-500359s was proposed to be derived
from phosphoenolpyruvate in a similar manner. Feeding with sodium [3-13C]pyruvate, however, only
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yielded a three-fold enrichment of the C-6′ position of 1 [27]. This relatively low enrichment was
therefore consistent with a different biosynthetic precursor for the C-5′ carboxamide in CarU, which
was ultimately determined to be L-α-Thr (vide infra). Finally, an eight-fold enrichment at both the
6′ ′ ′-methyl and the 3′-methoxy carbons was obtained upon feeding with [methyl-13C]L-Met, both of
which are consistent with S-adenosyl-L-methionine (AdoMet) as the biosynthetic precursor of the
methyl groups [27].
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3.2. Identification of the Gene Cluster
The biosynthetic gene clusters for A-500359s and A-503083s were reported in 2009 and 2010,
respectively [41,42]. The gene cluster for the A-500359s was first identified using reverse transcription
polymerase chain reaction (RT-PCR) with degenerate primers designed to amplify DNA fragments
encoding putative NDP-glucose-4,6-dehydratases (NGDH) [43], despite not having a clear role for
such an enzyme activity in A-500359 biosynthesis. Several high, low, and non-producing strains were
initially generated by chemical mutagenesis, thus providing a correlation of the abundance of the PCR
product versus production of A-500359s. A fragment of a putative NDGH that was over-expressed in
the high-producing strains and absent in non-producing strains was subsequently cloned to create a
digoxigenin (DIG)-labeled fragment, which was then used to probe a genomic library. Two contiguous
cosmids were identified and sequenced to reveal a 65-kb DNA region encoding 38 putative open
reading frames (orfs) (NCBI Accession No. AB476988). RT-PCR analysis was again utilized to analyze
the expression of these 38 orfs within the different producing and non-producing strains, revealing that
26 orfs were likely involved in A-500359 biosynthesis, regulation, and resistance. The development
of a genetic system within the 1 producing strain was unsuccessful. Therefore, to provide additional
evidence that the correct genomic locus was identified, one of these orfs—orf21 encoding a putative
aminoglycoside phosphotransferase—was heterologously expressed in 1-sensitive strains to reveal the
gene product confers selective resistance to 1.
To provide convincing evidence that the gene cluster for the capuramycin-type nucleoside
antibiotics was identified, the gene cluster for the A-503083s was targeted for cloning and
characterization [42]. As previously noted, A-503083s—unlike A-500359s—contain a 2′-O-carbamoyl
group, and it was therefore expected that a functional carbamoyltransferase was encoded within
the gene cluster. Interestingly, the gene cluster for A-500359s encodes an orf (orf8) with sequence
similarity to known carbamoyltransferases, but the orf8 gene product appears to be missing ~50% of
the internal sequence when compared to typical carbamoyltransferases. The orf8 gene remnant—along
with another expression-correlated orf encoding a putative nonribosomal peptide synthetase—were
utilized as probes to isolate four contiguous cosmids from the genomic DNA of the producing strain
Molecules 2019, 24, 433 5 of 17
of A-503083s. Sequencing of the four cosmids revealed ~81 kb-DNA encompassing 55 orfs (NCBI
Accession No. AB538860), of which 23 gene products annotated as CapA-W had high sequence
identity (72% to 91%) with those from the gene cluster of A-500359s (Figure 4 and Table 1). A putative
carbamoyltransferase (CapB) was discovered and, as expected, appeared to be full length and
functional based on bioinformatics analysis.
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Figure 4. Depiction of the genetic organization of the biosynthetic gene clusters for the
capuramycin-type nucleoside.
Table 1. Shared orfs within the cloned biosynthetic gene clusters.
Proposed Function A-500359 A-503083 A-102395
Fe(II)- and αKG-dependent dioxygenase orf7 capD cpr18
Capuramycin-2′-O-carbamoyltransferase orf8 capB NA
Putative 3-ketoreductase orf9 capC cpr20
Fe(II)-dependent, αKG:UMP dioxygenase orf10 capA cpr19
Putative 2,3-dehydratase orf11 capE cpr21
Putative 4-epimerase orf12 capF cpr22
PLP-dep ndent monooxygenase-decarboxylase orf12’ cap15 cpr23
Putative glycosyl transferase orf13 capG cpr24
L-Thr:uridine-5′-aldehyde transaldolase orf14 capH cpr25
Putative pyrophosphatase orf15 capI cpr26
Putative CO dehydrog nase orf16 capJ cpr28
Putative O-methyltransferase orf16’ capK cpr29
Putative CO dehydrogenase orf17 capL cpr30
Putative CO dehydrogenase orf18 capM cpr31
Putative ABC transporter orf19 capN NA
Putative ABC transporter orf20 capO NA
Capuramycin 3′ ′-phosphotransferase orf21 capP cpr17
UDP-glucose-4,6-dehydratase orf22 capQ NA
Glucose-1-phosphate thymidylyltransferase orf23 capR NA
Putative carboxyl methyltransferase orf24 capS cpr27
Putative L-ACL C-methyltransferase orf25 capT NA
Nonribosomal peptide synthetase orf26 capU NA
Nonribosomal peptide synthetase orf27 capV NA
Transacylase orf28 capW cpr51
Unlike with th producing train for A-500359s, an attempt to develo a genetic system in the
producer of A-503083s was initially successful. The capU gene, encoding a tridomain nonribosomal
peptide synthetase that was predicted to be involved in L-ACL formation, was inactivated [44].
The corresponding ∆capU strain was unable to produce the L-ACL-containing A-503083 A (6) and
A-503083 B (7) but instead produced relatively high levels of the deaminocaprolactam analog A-503083
F (11). Feeding the mutant strain with L-ACL restored the production of 6 and 7, revealing that
capU was ssential for the biosynthesis of the L-ACL component. Importantly, the results provided
the first direct genetic evidence that the genomic island was indeed essential f r the bi synthesis of
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A-503083s. Unfortunately, additional attempts to make other mutations within the producing strain of
the A-503083s have failed for unknown reasons.
The 13 gene cluster was identified in 2015 from a cosmid DNA library using a DIG-labeled
fragment of the L-Thr:uridine-5′-aldehyde transaldolase gene, which had already been characterized
from the gene cluster of the A-500359s and A-503083s and shown to be necessary for the biosynthesis
of the CarU moiety [45,46]. Four cosmids were sequenced, revealing 76 orfs within ~85-kb genomic
DNA (NCBI Accession No. KP995196). Of the identified orfs, 40 were proposed to be likely responsible
for the biosynthesis of 13; however, only 16 orfs were found to be shared among all three groups
of capuramycin-type antibiotics (Table 1). Therefore, it is proposed that 15 orfs are involved in the
biosynthesis of A-500359E (8), the likely last shared intermediate of all three biosynthetic pathways,
and one orf (cpr51) was responsible for the attachment of the polyamide via aminolysis. Similar to
the producing strain for A-503083s, a genetic system has been developed within the 13 producing
strain. Both ∆cpr25 and ∆cpr51 mutant strains have been independently prepared, and both mutations
abolished the production of 13. However, attempts to isolate biosynthetic intermediates or genetically
complement these mutations have so far been unsuccessful.
3.3. Functional Assignment of Gene Products
Insight into the biosynthesis of CarU was obtained from the independent efforts to characterize
the biosynthetic mechanism of the GlyU component of the liposidomycin-type nucleoside antibiotics.
Utilizing recombinant enzymes from the biosynthetic pathway for A-90289s, GlyU was shown to
be derived from UMP via two sequential enzyme-catalyzed reactions (Figure 5A). The first reaction
is catalyzed by LipL, a non-heme Fe(II)- and α-ketoglutarate (αKG)-dependent dioxygenase [47].
LipL stereoselectively hydroxylates C-5′ of UMP, resulting in the elimination of phosphate with
concomitant formation of the first pathway intermediate, uridine-5′-aldehyde (UA) [48]. Subsequently,
LipK, predicted to be a pyridoxal-5′-phosphate (PLP)-dependent serine hydroxymethyltransferase,
functions as a transaldolase by catalyzing the conversion of L-Thr and UA to GlyU and
acetaldehyde [45]. The LipK-catalyzed reaction was shown to be stereoselective both in the selection
of the L-Thr substrate and the formation of (5′S,6′S)-GlyU. Comparative bioinformatic analysis
revealed homologs to both LipL and LipK are encoded within the gene cluster for each group of
capuramycin-type antibiotics, suggesting that CarU is derived from UMP by way of (5′S,6′S)-GlyU.
If this is indeed the case, the direct precursor of the carboxamide of CarU would be expected to be
L-Thr instead of phosphoenolpyruvate as previously proposed. Consequently, feeding experiments
to probe the origin of C-6’ were revisited. As predicted from bioinformatics, L-[13C4,15N]Thr, when
fed to the producing strain of the A-503083s, resulted in a 15% enrichment at C-6′ of 7 (Figure 2) [46].
This level of enrichment is comparable to the levels for the enrichment of L-ACL with L-Lys, suggesting
that L-Thr is a direct precursor. Furthermore C-N J coupling suggested that the Cα-N bond of L-Thr
remained intact during CarU biosynthesis.
With this information in hand, the biosynthesis of CarU was examined using recombinant
enzymes. Cpr19, the LipK homolog encoded within the 13 gene cluster, was demonstrated to use
Fe(II), O2, and αKG to convert UMP to UA (Figure 5A) [46]. CapH and Cpr25, the LipK homologs
encoded within the A-503083s and 13 gene clusters, respectively, catalyzed the identical (and expected)
chemistry: the conversion of UA to (5′S,6′S)-GlyU, thus supporting the results from the feeding
experiments. The formation of (5′S,6′S)-GlyU as a pathway intermediate suggested downstream
chemistry involving C-6′-decarboxylation—shortening the heptose to a hexose, the introduction of
an O atom at C-6′, and oxidation. Given the precedence for PLP-dependent enzymes in catalyzing
decarboxylation of α-amino acids, the three gene clusters were analyzed for potential shared candidates
with a predicted PLP dependency. This search revealed one unassigned gene product (Cap15
for the biosynthesis of A-503083s) with similarity to bacterial PLP-dependent L-seryl-tRNA (Sec)
selemium transferase, which catalyzes the β-replacement of the hydroxyl group of tRNA-loaded L-Ser
with Se using selenophosphate as the Se source. However, no reaction was observed when Cap15
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was incubated with (5′S,6′S)-GlyU. Rather, serendipitously, Cap15 was discovered to function as a
PLP-dependent monooxygenase-decarboxylase that directly converts (5′S,6′R)-GlyU directly to CarU
in a single reaction (Figure 5A) [49]. The finding that Cap15 is stereoselective for the 6′R-isomer
of GlyU suggests an epimerase is needed to convert the CapH product to the Cap15 substrate.
One potential candidate for this reaction is CapD, an unassigned Fe(II) and αKG-dioxgenase with low
sequence similarity to Cpr19. Other members of this large dioxygenase superfamily—for example,
CarC—are known to catalyze epimerization at carbon centers bonded to an amine, thereby providing
precedence for this putative functional assignment [50–52]. Further biochemical characterization of
Cap15 revealed other intriguing properties including that (i) the enzyme activates molecular oxygen
using a substrate-PLP aldimine as the initial reducing agent, an unusual example of the use of the PLP
cofactor as a redox cofactor and (ii) the activity was dependent upon phosphate despite no obvious
role in the chemistry [49].Molecules 2019, 24, 433 7 of 17 
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pathway leading to uridine-5′-carboxamide (CarU). αKG, α-ketoglutarate; UA, uridine-5′-aldehyde;
PLP, pyridoxal 5′-phosphate; GlyU, 5′-C-glycyluridine. (B) Proposed biosynthetic pathway leading to
the 4,5-dehydro-D-manno-pyranuronate component. (C) Biosynthetic pathway leading to the formation
and attachment of the L-aminocaprolactam (L-ACL). (D) Group transfer reactions that occur after the
assembly of the signature capuramycin scaffold.
The enzymes required for the biosynthesis of the α-D-manno-pyranuronate component of the
capuramycin-type nucleoside antibiotics remain to be functionally assigned. If the moiety is derived
from D-mannose as the feeding experiments would suggest, the most direct path would involve
a four-electron oxidation of C-6, a 4,5-dehydration, and glycosyltransfer to CarU. Analysis of the
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biosynthetic gene clusters revealed several gene products with similarity to enzymes involved bacterial
sugar biosynthetic pathways, including a putative glycosyltransferase (CapG for A-503083) that could
catalyze the last step. However, it is not obvious how the other gene products, namely CapC, CapE, and
CapF for A-503083s, would contribute to the expected chemistry, which we propose begins from the
precursor GDP-mannose (Figure 5B). Nonetheless, the isolation of a taluronic acid-containing congener
of A-500359 H (10) called A-500359 J (14) suggests 4,5-dehydration occurs after CapG-catalyzed
transfer to the acceptor, CarU [20]. Additionally, this pathway would necessitate C-4′ epimerization to
generate GDP-taluronic acid, although it is not clear whether this occurs before or after glycosyltransfer.
As previously noted, the NDGH-like protein is not expected to play a role in α-D-manno-pyranuronate
biosynthesis since (i) a 4,6-dehydration catalyzed by the canonical NDGH is apparently not needed
and (ii) an NDGH homolog is not encoded within the 13 gene cluster.
The formation and attachment of the L-ACL moiety of the A-500359s and A-503083s has
been defined using enzymes from the biosynthetic pathway for A503083s, revealing two different
mechanisms for amide bond formation. The initial step in the biosynthesis involves a traditional
ATP-dependent reaction catalyzed by CapU: adenylation and transfer of L-Lys to the sulfhydryl
group of the carrier protein domain located at the C-terminus of CapU followed by intramolecular
aminolysis to release the lactam, the latter step of which appears to be nonenzymatic (Figure 5C) [44].
The subsequent step, the attachment of the L-ACL, involves an unusual ATP-independent
transacylation mechanism [42]. CapS first catalyzes an AdoMet-dependent carboxyl methylation
of 9 to generate the methyl ester A-500359 E (8). This reaction effectively “activates” the carboxylate
such that CapW—a protein with sequence similarity to AmpC β-lactamases that employ an active
site Ser residue to generate an acyl enzyme intermediate during the reaction coordinate—catalyzes
transacylation to produce methanol and the L-ACL-containing 1. Despite a dramatic difference in the
structure, the aryl-containing polyamide of 13 is expected to be attached in a similar manner due to
the uncovering of homologs of the carboxylmethyltransferase (Cpr27) and transacylase (Cpr51) [46].
However, enzymes catalyzing these putative reactions or any reactions involved in the biosynthesis of
the polyamide of 13 have been characterized to date. Finally, we propose that O-methylation of the
C-3′-hydroxyl is catalyzed by CapK and occurs prior to the attachment of the L-ACL since compounds
8 and 9 are isolated as the major congeners. However, the L-ACL-containing congener A-500359 G
(5) is produced in small amounts [24], suggesting either the amide coupling enzymes have relaxed
specificity toward this modification or the methylation can occur post L-ACL attachment.
Three enzyme-catalyzed group transfer reactions occur following the synthesis of 1, two of which
have been characterized in vitro (Figure 5D). CapB, the predicted full-length carbamoyltransferase
that was used in part to identify the biosynthetic gene cluster for the A-503083s, catalyzes the
carbamoyl phosphate-dependent addition of a carbamoyl group to the C-2′ hydroxyl to convert 1 to 7
(assuming this “tailoring” step occurs first) [42]. CapT, a putative radical SAM C-methyltransferase,
likely catalyzes the stereoselective methylation of the L-ACL, thereby converting 7 to 6 (assuming
this reaction follows CapB). Finally, CapP was functionally assigned as an ATP-dependent 7
3′ ′-O-phosphotransferase that was shown to likely confer self-resistance to the producing strain [53].
Cpr17, the CapP homolog in the 13 biosynthetic pathway, was similarly demonstrated to have an
identical phosphotransferase function [54]. Nonetheless, phosphorylated capuramycin analogs have
not been isolated from the producing strains.
4. Chemical and Enzymatic Synthesis of Capuramycin and Analogs
Since the structural elucidation of capuramycin in 1988 [33], a few total syntheses have been
independently reported. Moreover, a large library of analogs prepared via semisynthesis, total
synthesis, and biocatalysis have been screened for antibacterial activity. These efforts, which have
resulted in the advancement of a few lead compounds for further development, are described below.
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4.1. Total Synthesis
The total synthesis of 1 was first reported in 1994 (Figure 6) [55]. This synthesis utilized a mostly
linear, 22-step approach involving convergence of an α-D-manno-pyranuronate sugar donor 15 and
protected L-talo-uridine as the sugar acceptor 16. The synthesis of 16 started from diacetone glucose,
going through a 13-step sequence with a 27% overall yield. Acetyl-protected mannopyranose was used
to prepare 15 in four steps. The synthesized product confirmed the proposed structure including the
absolute configuration of 1 that was initially deduced upon structural characterization of the natural
product. An improved total synthesis of 1 was reported in 2009 using 15 linear steps [56]. Starting from
the cyanohydrin intermediate 17, 1 was synthesized in eight steps with overall 30% yield utilizing the
aldehyde derivative 18 as an intermediate. The synthesis was further improved by adopting a new
protecting group—a monomethoxydiphenylmethoxymethyl (MDPM) group [57]—that is more stable
under diverse conditions and can be adequately removed in 30% trifluoroacetic acid [58].
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4.2. Preparation of 1 Analogs
The synthesis of analogs of 1 (Table 2) was initially pursued shortly after the discovery of 1 to 12
using a semisynthetic strategy to substitute the L-ACL component by starting with congener 8 [59].
With strong nucleophilic amines, a single-step aminolysis reaction afforded the products in decent
yields. Alternatively, a multistep protection-deprotection sequence that included saponification and
condensation was utilized. Sixty-eight capuramycin analogs, represented by 19 to 26, were prepared.
A few of these analogs displayed improved TL1 inhibition and antibacterial activity against various
Mycobacterium species including M. smegmatis, M. avium, M. intracellulare, and M. kansasii [31]. Of the
analogs tested, 24 (compound 65 in the original paper), which has a 3,4-difluoroaniline in place of the
L-ACL, showed improved MIC values (0.5 to 2 µg/mL compared to 8 to 12.5 µg/mL for 1).
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Table 2. Antimycobacterial activities of several capuramycin analogs prepared through semisynthesis.
TL1 IC50
(ng/mL)
MIC (µg/mL) 1
Compound R1 R2 R3 Strain A Strain B Strain C Strain D
20 PhNH- - - 6.5 6.25 16 4 8
21 PhN(Me)- - - 7.6 12.5 4 1 8
22 3-F-PhNH- - - 10 6.25 2 2 8
23 4-F-PhNH- - - 37 6.25 4 2 2
24 3,4-F2-PhNH- - - 9 6.25 2 0.5 1
25 4-Cl-PhNH- - - 18 6.25 4 2 16
26 4-Br-PhNH- - - 20 6.25 8 0.5 8
27 - H H(CH2)11CO- n.d. 3.13 <0.063 0.125 0.125
28 - Me H(CH2)9CO- 550 6.25 <0.063 <0.063 <0.063
1 10 12.5 8 8 8
2 10 6.25 8 4 16
RIF 2 n.d. 0.125 0.125 0.25
IZD 3 n.d. 1 8 2
1 Strain A: M. smegmatis SANK75075; strain B: M. avium NIHJ1605; strain C: M. intracellulare ATCC19543; strain D:
M. kansasii ATCC12478; 2 Rifampicin; 3 Isoniazid
Additional studies focused on the modification of the 2′-hydroxyl of 1 and 2 by introducing
different acyl, alkoxycarbonyl, or alkylether groups in three to five steps (Table 2) [60]. Fifty-one
analogs were synthesized and tested for antimycobacterial activity with a few showing improved
activity compared to the parent compounds (Table 2). Among them, 28 (compound 20 in the original
paper), which has a decanoyl chain, showed improved MIC against the four species of Mycobacterium.
Interestingly, 28 was 55-fold less potency against TL1 when compared to the parent compound, 2.
The improved MIC of 28 was hypothesized to be due to the increased lipophilicity that results in the
effective penetration of the Mtb cell wall, thus compensating for the decrease in IC50 (assuming the
acyl group remains intact, which remains to be determined). Indeed, the penetration of Mtb cell walls
has been a major challenge in the field of anti-TB drug discovery, and comparable acylation strategies
for other drug classes of potential anti-TB drugs have been shown to have a similar effect [61,62].
In total, over 7000 capuramycin analogs were synthesized using different combinations of
the aforementioned semisynthetic approaches and screened for antimycobacterial activity [63,64],
ultimately yielding 24 (named RS-124922 by Sankyo Co.; renamed to SQ922 by Sequella Inc. after
licensing the library), and 28 (RS-118641; SQ641) as leads [65,66]. In comparison to parent 2 (RS-112997;
SQ997), compound 28 displayed a significantly improved antimycobacterial activity with MICs as
follows: 1 µg/mL against non-MDR Mtb (n = 22 clinical isolates; 16 µg/mL for 2), 0.5 µg/mL against
MDR-Mtb (n = 11; 16 µg/mL for 2), 4 µg/mL against M. avium (n = 33; 8 µg/mL for 2), and 0.06 µg/mL
against M. intracellulare (n = 17; 2 µg/mL for 2) [65]. By further examining the activity against Mtb
H37Rv, compounds 24 and 28 were shown to kill faster than other clinically used anti-TB drugs
including isoniazid and rifampicin [65]. Both analogs appear to induce bacteriolysis of Mtb, and 28 had
a clear post-antibiotic effect that lasted as long as 55 h. Compound 28 also showed synergistic activity
with other anti-TB drugs, including streptomycin and ethambutol [65]. Finally, when formulated with
a vitamin E derivative or as micelles and tested in vivo, 28 displayed ~2 log reduction in burden using
a murine lung model of Mtb H37Rv infection [66]. No noticeable toxicity was observed.
The impact of different long chain ester modifications at the 2′, 2′ ′, and/or 3′ ′ positions of 2,
24, and 28 has been explored as a strategy to improve activity against mycobacteria and extend
the antibiotic spectrum (Figure 7) [67,68]. Promising results were obtained when conjugated
with decanoic acid (DEC) or amino undecanoic acid (AUA) exemplified by compounds 29 to
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35. With respect to the antibiotic spectrum, compounds 28-3′ ′-AUA (29), 2-2′,2′ ′,3′ ′-triAUA (33),
and 24-2′-DEC (34) showed a gain in the spectrum as desired, generating compounds active
against Escherichia coli, Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus, and/or
vancomycin-resistant Enterococcus [67]. The activity against Staphylococcus aureus was further improved
by co-administration with phenylalanine arginine β-naphthyl amide, an efflux pump inhibitor.
The addition of ethylenediaminetetraacetic acid elicited similar improvements to activity against
Gram-negative bacteria. The conjugation of AUA in general enhanced the intracellular killing against
Mtb H37RV, although the overall effect was minimal. Nonetheless, it was clear from these studies that
AUA moieties were superior to DEC; for example, conjugation of two AUA moieties on 28 (30) led
to a slight decrease of antimycobacterial activity whereas conjugation of two undecanoic acid (UA)
moieties to generate 31 caused complete loss of antibacterial activity [67]. This result suggested that
the additional amino groups on the AUA moieties improve the permeability of capuramycin and/or
affect drug efflux. The metabolic fate of the acyl chains—which might be prone to hydrolysis by the
numerous Mtb esterases that have been recently characterized [62,69]—awaits further testing.
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More recently, 28 was demonstrated to be effective in Clostridium difficile infection (CDI) treatment
in a murine model [70]. Although treatment with 28 at >1 mg/kg/day for 5 days was shown to have
similar efficacy to vancomycin—a first-line therapy for CDI—at 20 mg/kg/day during the initials
stages of infection, the post-antibiotic effects such as mice survival rates and reduced weight loss were
significantly improved with 28.
In addition to a semisynthetic approach, total synthesis has also been successfully used to generate
novel capuramycin analogs for structure-activity relationship studies (Figure 6B) [58,71,72]. Of the
~100 analogs prepared, perhaps the most promising result has been achieved by examining the effects
of differential O-methylation of the ribose of the CarU component (Figure 8). The absence of the
3′-O-methyl group of 1 yielded an inactivate analog (36). Swapping the position of the methyl group
to generate the 3′-desmethyl, 2′-O-methyl-1 (37) yielded an analog with similar TL1 inhibitory activity
and antimycobacterial activity compared to 1. However, neither 1 nor 37 was effective against dormant
Mtb. Contrastingly, the 2′-O,3′-O-dimethyl-1 (38, named UT01320) not only killed replicating but
also nonreplicating Mtb. Compound 38 unexpectedly did not inhibit TL1 but instead inhibited RNA
polymerase from M. smegmatis and S. aureus with the IC50 values of 0.1 to 0.15 µM [72]. Furthermore,
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38 and 24 were strongly synergistic, suggesting that inhibiting these two distinct targets is a promising
approach warranting additional studies.
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Finally, a biocatalytic approach has been reported as a complimentary strategy to semi- and
total-synthetic efforts [54]. This approach took advantage of the discovery of the enzymatic activity of
CapW, a transacylase that utilizes the methyl ester of 11 as an acyl donor and L-ACL as the acyl acceptor
to generate a new amide bond (Figure 9). Compound 12 was isolated as the major congener from the
∆capU mutant strain and converted to 11 via chemical or enzymatic synthesis. Subsequently, incubation
of CapW with 11 and different amine acceptors gave the corresponding analogs in modest yields.
Amine acceptors with carboxylate functionalities (for example, α-amino acids) were not incorporated
by CapW; however, this limitation could be overcome by using methyl esters or Boc-protected α-amino
acids. Further interrogation into the biochemical properties of CapW revealed the enzyme not only
performed an amide–ester exchange reaction but could also catalyze a direct transamidation reaction
with 7—isolated with decent yields from the wild-type strain—as the acyl donor, thereby substituting
the L-ACL in a single-step reaction. Using both acyl exchange strategies, a total of 43 analogs were
synthesized using nonnative amines as acyl acceptors. Biological activity assays indicated that a few
of the analogs had significantly improved antibacterial activity against M. smegmatis and Mtb H37Rv.
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5. Prospects
The re-discovery of the capuramycin scaffold, the parent of which was first isolated in 1986
based on antibacterial activity, has sparked significant efforts aimed at preparing analogs for antibiotic
discovery and development. To date the most fruitful results have been achieved using semisynthetic
modification of the parent natural product with an emphasis on L-ACL substitution starting from 8 or
Molecules 2019, 24, 433 13 of 17
acylation of the reactive hydroxyl groups of 2. The semisynthetic strategy has led to the discovery of
a few analogs such as 24 and 28 that have superior activity against Mtb in comparison to the parent.
Furthermore, some of the analogs have an extended spectrum of activity, suggesting the development
of capuramycin-type nucleoside antibiotics is not limited to mycobacteria. Formulation and delivery
studies [73–76] have further improved the solubility and pharmacodynamics of some of these lead
compounds, thereby pushing this family further down the translational pipeline.
Total synthesis and enzymatic synthesis have more recently emerged as two alternative strategies
to generate capuramycin analogs. Importantly, both strategies afford an opportunity to probe the
structure–activity relationship of core components of the capurmaycin scaffold in greater detail.
The former approach has enabled the synthesis of new L-ACL-substituted analogs and the dimethylated
analog 38. The latter approach has enabled a chemoenzymatic strategy to likewise synthesize
new L-ACL-substituted analogs. Unfortunately, most of the enzyme-catalyzed steps involved in
capuramycin biosynthesis remain undefined, particularly with respect to the formation and attachment
of the α-D-manno-pyranuronate. As our understanding of the biosynthetic pathway improves, it is
expected that capuramycin scaffolds altered within the α-D-manno-pyranuronate or elsewhere can be
readily prepared through enzymatic synthesis, thereby generating a new array of analogs that will be
valuable for continued anti-TB drug discovery efforts.
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